Intracerebral Hemorrhage on Apixaban: Reversal, Blood Pressure, and Restart
A 74-year-old man with atrial fibrillation (CHA2DS2-VASc 5) taking apixaban 5 mg twice daily for 3 years is brought in after sudden headache and left-sided weakness. Last apixaban dose was 8 hours ago. CT shows a 30 mL right basal ganglia hemorrhage with intraventricular extension and mild midline shift; GCS is 12. BP 190/100 mmHg, HR 78 bpm, weight 88 kg, creatinine 1.3 mg/dL (CrCl ~55 mL/min). Platelets 210,000/µL, INR 1.1, hemoglobin 13.8 g/dL. Neurosurgery is at the bedside; the pharmacy has andexanet alfa on formulary, and 4F-PCC is available. He is not on any antiplatelet agent.
1. What reversal strategy do you recommend, and how does the timing of his last dose and drug dose drive the choice?
Read the worked answer
Therapeutic anticoagulation must be reversed promptly - a 30 mL basal ganglia hemorrhage with intraventricular extension and midline shift is life-threatening, and apixaban effect persists for roughly 24 hours after the last dose.
Andexanet alfa, low-dose regimen, is appropriate here: 400 mg IV bolus at 6 mg/min, then 4 mg/min for 120 minutes. Low-dose is correct because he takes apixaban 5 mg (not >5 mg), and the last dose was 8 hours or more ago. High-dose (800 mg bolus/8 mg/min) applies to apixaban >5 mg, rivaroxaban >10 mg, unknown dose, or last dose <8 hours.
If andexanet is unavailable, contraindicated, or unaffordable: 4F-PCC 50 units/kg (~4400 units) - this is the guideline-endorsed alternative and should not be delayed. Do not wait for a drug-specific anti-Xa level; a normal PT does not exclude apixaban effect.
Also: stop apixaban, avoid platelet transfusion (no antiplatelet on board), do not give vitamin K or FFP (no warfarin; volume load without benefit). Tranexamic acid is not recommended for spontaneous ICH.
2. How do you manage his blood pressure, and what else belongs in the first 24 hours?
Read the worked answer
Target systolic BP ~140 mmHg (range 130–150) - smooth, sustained control, avoiding both sustained SBP >150 and rapid drops below 130 that could compromise penumbra and renal perfusion.
Agent: nicardipine infusion, start 5 mg/h, titrate by 2.5 mg/h every 5–15 minutes. Labetalol boluses (10–20 mg) are an alternative but avoid with bradycardia or reactive airway disease. Avoid nitroprusside (raises ICP via cerebral vasodilation) and avoid nitroglycerin as the primary agent.
First 24 hours - additional items:
- Neurosurgery/stroke neurology: discuss EVD for intraventricular hemorrhage and hydrocephalus.
- Head of bed 30°, neutral neck, avoid hypoxia and hypercapnia.
- Osmotherapy (hypertonic saline or mannitol) if there are signs of herniation or clinical deterioration.
- Glucose 140–180 mg/dL, normothermia, seizure treatment if clinical or electrographic seizures.
- Repeat CT if GCS drops; hematoma expansion most often happens in the first 6 hours.
- DVT prophylaxis with intermittent pneumatic compression only until hemostasis is assured.
Do not "bridge" with heparin at any point.
3. The family asks when anticoagulation can be restarted. How do you frame the decision for atrial fibrillation after ICH?
Read the worked answer
There is no single right answer - this is a shared decision with neurology, neurosurgery, and cardiology. Frame it around competing risks.
Typical timing: for atrial fibrillation with a high stroke risk (his CHA2DS2-VASc is 5, roughly 4–6%/year untreated), restart oral anticoagulation at about 4 weeks after the hemorrhage, once imaging shows no expansion and he is clinically stable. Lower-risk patients or those with lobar/microbleed-pattern hemorrhages can wait longer (8–12 weeks). Very high ischemic risk (mechanical valve, recent cardioembolic stroke) may justify earlier restart, but that is not his situation.
Agent: a DOAC is preferred over warfarin - apixaban has the lowest ICH rate among DOACs. Full dose 5 mg twice daily applies (dose reduction requires 2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL - he has none of these).
Do not bridge with enoxaparin or heparin; bridging increases bleeding without reducing stroke.
If anticoagulation is judged prohibitive, refer for left atrial appendage occlusion.
Document the reasoning in the chart; the decision will be revisited at every admission. Address fall risk, blood pressure control, and avoidance of NSAIDs and antiplatelets.